[HTML][HTML] IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

M Ayers, J Lunceford, M Nebozhyn… - The Journal of …, 2017 - Am Soc Clin Investig
M Ayers, J Lunceford, M Nebozhyn, E Murphy, A Loboda, DR Kaufman, A Albright…
The Journal of clinical investigation, 2017Am Soc Clin Investig
Programmed death-1–directed (PD-1–directed) immune checkpoint blockade results in
durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-
γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host
cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti–
PD-1 therapies, including pembrolizumab. However, whether quantifying T cell–inflamed
microenvironment is a useful pan-tumor determinant of PD-1–directed therapy response has …
Programmed death-1–directed (PD-1–directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti–PD-1 therapies, including pembrolizumab. However, whether quantifying T cell–inflamed microenvironment is a useful pan-tumor determinant of PD-1–directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell–inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell–inflamed GEP contained IFN-γ–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell–inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
The Journal of Clinical Investigation